Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BYC9
UPID:
RM20_HUMAN
Alternative names:
39S ribosomal protein L20, mitochondrial
Alternative UPACC:
Q9BYC9; B2RE41; B7Z746
Background:
The Large ribosomal subunit protein bL20m, also known as 39S ribosomal protein L20, mitochondrial, plays a crucial role in the synthesis of proteins within the mitochondria. Its involvement in the mitochondrial ribosome highlights its importance in cellular energy production and overall mitochondrial function.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein bL20m could open doors to potential therapeutic strategies. Its pivotal function in protein synthesis within mitochondria suggests that targeting this protein could influence mitochondrial diseases and disorders related to cellular energy metabolism.